Psychotropic medication in pregnancy: Ethical aspects and clinical management

Journal of Perinatal and Neonatal Nursing

Volumn 18, Issue 3, 2004, Pages 194-205

  Allison, Sarah K ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Mental illness; Pregnancy; Psychotropic medication; Women's health

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLOMIPRAMINE; CLONAZEPAM; CLORAZIL; CLOZAPINE; DIAZEPAM; DIETHYLSTILBESTROL; DOXEPIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE MALEATE; HALOPERIDOL; IMIPRAMINE; KLONADINE; LITHIUM; METHYLPHENIDATE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PROXILIN; PSYCHOTROPIC AGENT; RISPERIDONE; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE; ZIPRAZIDONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT;

ADENOCARCINOMA; ALCOHOLISM; ANXIETY DISORDER; BIPOLAR DISORDER; CARDIOVASCULAR RISK; CLEFT LIP; CLINICAL TRIAL; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; CYANOSIS; DEPRESSION; DISEASE EXACERBATION; DRUG WITHDRAWAL; FETUS RISK; FETUS WASTAGE; HEALTH CARE; HEALTH PRACTITIONER; HUMAN; HYPEREMESIS GRAVIDARUM; HYPERREFLEXIA; HYPOPLASIA; HYPOTHYROIDISM; IRRITABILITY; LIVER FAILURE; LOW BIRTH WEIGHT; MEDICAL DECISION MAKING; MEDICAL ETHICS; MENTAL DISEASE; MENTAL HEALTH; MENTAL HEALTH CARE; MOTHER FETUS RELATIONSHIP; MUSCLE HYPOTONIA; NEPHROGENIC DIABETES INSIPIDUS; NEURAL TUBE DEFECT; NONHUMAN; NURSING; PERINATAL CARE; PERINATAL PERIOD; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PREMATURITY; PRENATAL DRUG EXPOSURE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL ASPECT; STILLBIRTH; TACHYCARDIA; TERATOGENICITY; TREMOR; URINE RETENTION; ADULT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; FETUS; FETUS DISEASE; MATERNAL WELFARE; NEWBORN; PREGNANCY COMPLICATION; WOMEN'S HEALTH;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ETHICS, CLINICAL; FEMALE; FETAL DISEASES; FETUS; HUMANS; INFANT, NEWBORN; MATERNAL WELFARE; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTROPIC DRUGS; WOMEN'S HEALTH;

EID: 7944228998     PISSN: 08932190     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005237-200407000-00003     Document Type: Review

References (44)

1. US Census Bureau. Population data. Population division, 2001. Available at:http://www Retrieved CK%20&%20future%20pubs/National%20Estimates. htm. Accessed January 10, 2004.
2. Bruns CM, Timble C. Rising tide: taking our place as young feminist psychologist. Women Ther. 2001;23:9-36.
3. Sheridon J. In America [videotape]. Culver City, Calif: Searchlight Pictures; 2003.
4. Ross H. Steel Magnolias [videotape]. Beverly Hills, Calif: Columbia Tristar Home; 1989.
5. Farmer RL. Gender and psychotropics: toward a third wave framework. Br J Soc Work. 2003;33:611-623.
6. Walker LO, Wilging S. Rediscovering the "M" in MCH: maternal health promotion after childbirth. J Obstet Gynecol Neonatal Nurs. 2000;29:229-236.
7. Tillet J, Kostich JM. Use of over-the-counter medications during pregnancy. J Perinat Neonatal Nurs. 2003;17:3-18.
8. Newport JD, Wilcox MM, Stowe ZN. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Semin Perinatal. 2001;25:3177-3190.
9. Mellin GW, Katzenstein M. The saga of thalidomide (concluded). Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med. 1962;267:1238-1244.
10. Pyne JM, Patterson TL, Kaplan RM, Gillin JC, Koch WL, Grant I. Assessment of the quality of life of patients with major depression. Community Ment Health J. 1997;48:224-230.
11. Kaiser Family Foundation. Special report: the last-chance contraceptive (part 1 of 2). January 14, 2002. Available at: http://www.massnaral.org/what we_do/ Gain access_files/unintended_pregnancy_facts.shtml. Accessed January 10, 2004.
12. American Medical Women's Association. Emergency contraception fact sheet. Available at: http:// www.massnaral.org/what we_do/Gain access_files/ unintended_pregnancy_facts.shtml. Accessed January 10, 2004.
13. Ward RM. Difficulties in the study of adverse fetal and neonatal effects of drug therapy during pregnancy. Semin Perinatal. 2001;25:191-195.
14. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(suppl 4):42-55.
15. Reebye PN, Morrison SJ, Panikkar H, Misri S, Grunau RE. Affect expression in prenatally psychotropic exposed and nonexposed mother-infant dyads. Infant Ment Health J. 2002;23:403-416.
16. Miller LJ. The use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-450.
17. Food and Drug Administration. Labeling and prescription drug advertising: content and format for labeling for human prescription drugs. Fed Regist. 1980;44:37434-37467.
18. Goldaber KG. Psychotropics. Semin Perinatol. 1997;21:154-159.
19. Chaudron LH. Psychiatric disorders across the female life cycle. Paper presented at: the Psychopharmacology Update, Baylor College of Medicine; September 6, 2001; Houston, Tex.
20. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs and Pregnancy and Lactation. 6th ed. Philadelphia; Lippincott Williams & Wilkins; 2001.
21. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effects of phenothiazines in human beings. Teratology. 1977;15:57.
22. Erriksson M, Billing L, Steneroth G, Zetterstrom R. Health and development of 8-year-old children whose mothers abuse amphetamine during pregnancy. Acta Paediatr Scand. 1989;78:944-949.
23. Swaan AC. Major system toxicities and side effects of anticonvulsants. J Clin Psychiatry. 2001;62(suppl 14):16-21.
24. Pastuszak A, Schick-Boschetto B, Zuber C. Pregnancy outcome following first trimester exposure to fluoxetine (Prozac). JMMA. 1993;269:2246-2248.
25. Chambers CD, Johnson KA, Dick LM, et al. Birth out-comes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010.
26. Steiner M, Yonkers KA, Eriksson E, ed. Mood Disorders in Women. London: Martin Dunitz Ltd; 2000.
27. Kulin NA. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA. 1998;279:609-610.
28. Van Waes AV, van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemisis gravidarum. J Clin Pharmacol. 1969;9:224.
29. Altshuler LL, Cohen L, Scuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric-illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153:592-606.
30. Brinckmann J, Blumenthal M. Goldberg A. Herbal Medicine: Expanded Commission E Monographs. Newton, PA: Integrative Medicine Communication; 2000.
31. Stewart GW. Emotional responses and mood disorders. In: Stewart G, ed. Principles and Practice: Psychiatric Nursing. 6th ed. St Louis: Mosby; 1998:348-384.
32. Chambers CD, Johnson KA, Lyn M, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
33. Nulman I, Rovet J, Steward D, et al. Neurodevelopment of children exposed in utero to antidpressant drugs. N Engl J Med. 1997;336:258-262.
34. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychological Nursing; 1994:393-444.
35. Villeponteaux VA, Lydiard RB, Laraia MT, et al. The effects of pregnancy on preexisting panic disorder. J Clin Psychiatry. 1992;53:201-203.
36. Cohen LS, Rosenbaum JF. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry. 1998;59(suppl 2):18-28.
37. Dunkel-Schetter C, Lobel M. Pregnancy and childbirth. In: Blechman EA, Brownell KD, eds. Behavioral Medicine and Women. New York: Guilford Press; 1998:137-146.
38. Weisberg RB, Paquette JA. Screening and treatment of anxiety disorders in pregnant and lactating women. Women Health Issues. 2002;12:32-36.
39. Moller MD, Murphy MF. Neurobiological responses and schizophrenia and psychotic disorders. In: Stewart G, ed. Principles and Practice: Psychiatric Nursing. 6th ed. St Louis: Mosby; 1998:405-438.
40. O'Hara MW. Postpartum Depression: Causes and Consequences. New York: Springer-Verlag; 1994.
41. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991;48:1082-1088.
42. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of utero exposure to lithium. JAMA. 1994;271:146-150.
43. Littrell KH, Johnson CT, Peabody CD, Hilligoss N. Antipsychotics during pregnancy [Letter to the editor]. Am J Psychiatry. 2000;157:1342.
44. Llewellyn A, Stowe ZN, Strader JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry. 1998;59(suppl 6):57-64.